Sundry Photography Xencor ( NASDAQ: XNCR ) said it will regain the exclusive worldwide rights to plamotamab from Johnson & Johnson’s ( JNJ ) Janssen unit. Janssen and Xencor entered into a partnership in 2021 to develop and commercialize plamotamab and novel B-cell targeting bispecific antibodies. Xencor had advanced plamotamab through Phase 1 testing for hematologic cancers, the company said.
Xencor said the Phase 1 data for plamotamab in patients B-cell malignancies demonstrated the therapy was well tolerated with encouraging clinical activity. Janssen has retained the rights to two other bispecific antibodies, JNJ-9401 and JNJ-1493. Both drug candidates entered into clinical development in Q4 2023.
More on Xencor Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial information for Xencor.
